

Monday, November 5, 2018

11:00am-12:00pm	Check-In and Light Lunch
12:05-12:10pm	Welcome & Introduction - Van Huynh, MD
Sessions Begin	
12:10-12:50pm	<ol style="list-style-type: none"> Update on FDA Approved CAR- T cell products: <ul style="list-style-type: none"> KITE Pharmaceuticals/Gilead – <i>Remus Vezen, MD, PhD</i> Novartis/CHOP/UPENN - <i>Shannon Maude, MD, PhD</i>
12:50-1:35pm	<ol style="list-style-type: none"> Update on CAR-T Cell Trials: <ul style="list-style-type: none"> Seattle Children's - <i>Rebecca Gardner, MD</i> Memorial Sloan Kettering - <i>Jae Park, MD</i> CHOP Humanized CAR-T Cell Trial - <i>Shannon Maude, MD</i>
1:35-1:55pm	Q & A Panel Session (15 min) Moderator Jeffrey Miller
1:55-2:40pm	<ol style="list-style-type: none"> Future Direction of CD 19 CAR-T Cell Trials <ul style="list-style-type: none"> Multispecific CAR-T Cell Targeting in ALL: What does the future hold? <i>Nirali Shah, MD, MHSc (NCI Pediatric Branch)</i> Bispecific CAR-20.19-T cells for Relapsed, Refractory B-cell NHL- Nirav Shah, MD <i>(Medical College of Wisconsin)</i> Future Direction of NK CAR Cell Trials <ul style="list-style-type: none"> Making NK cells antigen specific with TriKEs and CARs - Jeffrey Miller, MD <i>(University of Minnesota)</i>
2:40-2:55pm	Q & A Panel Session (15 min) Moderator Sarah K. Tasian
2:55-3:25pm Break (30 min)	
3:25-3:45pm	4. CAR-T cell therapy in Europe - Andre Baruchel, MD (University Hospital, Paris)
3:45-4:05pm	5. Long-term toxicities and follow up of Patients Receiving CAR-T Cell Therapy – Michael A. Pulsipher, MD (CHLA)
4:05-4:20pm	Q & A Panel Session (15 min) Moderator Rebecca Gardner
4:20-4:40 pm	6. Bench-to-Bedside: New trials in development for genetic subtypes of ALL and AML - Sarah K. Tasian, MD (CHOP)
4:40-5:00pm	7. What is the role of HSCT in the world of immune-biopharmaceuticals and CAR-T cells? Are CAR-T cells a bridge to HSCT or can it replace HSCT? - Michael A. Pulsipher, MD (CHLA)
5:00-5:20pm	8. The Economics of CAR-T Cell Therapy - Richard Maziarz, MD (Oregon Health Sciences University)
5:20 - 5:40pm	Q & A Panel Session (20 min) Moderator Jae Park
5:40-6:40 pm	<ol style="list-style-type: none"> Clinical Updates: <ul style="list-style-type: none"> Daratumumab - David Teachey, MD (CHOP) Blinatumomab - Patrick Brown, MD (John Hopkins Medical Center) Inotuzumab ozogamicin in Adult ALL - Anjali Advani, MD (Cleveland Clinic) Inotuzumab ozogamicin in Pediatric ALL - Maureen O'Brien, MD (Cincinnati Children's)
6:40-6:55pm	Q & A Panel Session (15 min) Moderator Jim Whitlock, MD
7:30pm	Invited Faculty Dinner

Tuesday, November 6, 2018

6:30-8:00am	Breakfast
8:05-8:10am	Welcome & Introduction – Van Huynh, MD
Sessions Begin	
8:10-8:30 am	1. NK cell Biology – Mike Caligiuri, MD (City of Hope)
8:30-9:10 am	2. International Update <ul style="list-style-type: none"> • Update from United Kingdom – John Moppett, MB, PhD (Bristol Royal Hospital for Children) ▪ Update from France – Andre Baruchel, MD (University Hospital, Paris)
9:10-9:25am	Q & A Panel Session (15 min) Moderator Sima Jeha
9:25-10:20am	3. Clinical Research Trials <ul style="list-style-type: none"> ▪ St. Jude Protocols: Novel, non-immunotherapeutic approaches to relapsed leukemia – Jeffrey E. Rubnitz, MD, PhD ▪ Current and planned trials from ECOG-ACRIN – Mark Litzow, MD (MAYO Clinic) ▪ MD Anderson Protocols – Nicholas Short, MD ▪ Alliance Clinical Trials – Wendy Stock, MD (University of Chicago)
10:20-10:35am	Q & A Panel Session (15 min) Moderator Sue Rheingold
10:35-10:50am Break (15 min)	
10:50-11:40am	4. Moving forward in pediatric ALL: Upcoming COG trials – Elizabeth Raetz, MD (NYU) Moving forward in AYA ALL: Jennifer McNeer, MD – (University of Chicago) Moving forward in adult ALL – Matt Wieduwilt, MD, PhD (UCSD)
11:40-11:55am	Q & A Panel Session (15 min) Moderator Wendy Stock
11:55-1:10pm Lunch (1 hr 15 min)	
1:10-1:50pm	5. Relapse/Minimal Residual Disease (MRD): <ul style="list-style-type: none"> ▪ Redefining Relapse – Should patients with +MRD be eligible for clinical trials? – Paul Gaynon, MD (CHLA) 6. MRD: Next generation sequencing in COG – David Wu, MD, PhD (University of Washington)
1:50-2:05pm	Q & A Panel Session (15 min) - Moderator Michael Borowitz
2:05-2:35pm	7. Asparaginase <ul style="list-style-type: none"> • Asparaginase and silent inactivation – Van T. Huynh, MD (CHOC Children’s) • Asparaginase toxicity and management – Carol Lin, MD (CHOC Children’s)
2:35-3:15pm	8. Supportive Care for ALL patients <ul style="list-style-type: none"> • The influence of obesity on toxicity and survival of ALL patients – Etan Orgel, MD (CHLA) • Onco-fertility: Parenthood options for AYAs after cancer treatment – Laxmi A. Kondapalli, MD, MSCE (Colorado Center for Reproductive Medicine)
3:15-3:30pm	Q & A Panel Session (15 min) Moderator Deepa Bhojwani
3:30-3:35pm	Summation and Concluding Remarks